The single blind randomized control trial for preventing post-ERCP pancreatitis by NSAID injection, flurbiprofe
Not Applicable
Recruiting
- Conditions
- post-ERCP pancreatitis
- Registration Number
- JPRN-UMIN000009121
- Lead Sponsor
- School of Medicine, Keio University Division of Gastroenterology & Hepatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 398
Inclusion Criteria
Not provided
Exclusion Criteria
people who does not understand the contents of this research aims and methods before ERCP
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method incidence and severity of post-ERCP pancreatitis
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie flurbiprofen's COX-2 inhibition in preventing post-ERCP pancreatitis?
How does intravenous flurbiprofen compare to rectal NSAIDs for post-ERCP pancreatitis prevention in clinical trials?
Which inflammatory biomarkers predict response to flurbiprofen in high-risk post-ERCP pancreatitis patients?
What are the safety profiles of injectable flurbiprofen versus other NSAIDs for post-ERCP pancreatitis prophylaxis?
Are there combination therapies involving flurbiprofen and corticosteroids for post-ERCP pancreatitis prevention?